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Abstract
Thyroid cancer (TC) represents less than 1% of all newly diagnosed malignancies. In some selected cases, with a high clinical 
suspicion for disease but negative I-131 scan, positron emission tomography/computed tomography (PET) with F-18-Fluorode-
oxyglucose (FDG) could be helpful in the detection of disease and the definition of its extent. FDG PET/CT, better if performed 
after TSH stimulation analogously to patient preparation done for radioiodine scintigraphy, could be useful mainly in the detec-
tion of metastatic and recurrent disease since the uptake and diagnostic sensitivity of FDG are increased by TSH stimulation. 
Recently, the role of oncogenic mutations in the tumorigenesis of TCs has become clearer. Among such mutations, BRAFV600E 
represents the most common genetic alteration. Mutated BRAF may define a more aggressive papillary carcinoma with poorer 
prognosis and therefore its analysis has been extensively studied as a rule-in test for thyroid carcinoma.
In this paper, we try to outline the possible role of FDG PET/CT in the management of patients with TC and positive BRAF 
mutations and the impact that it could have on their therapeutic algorithm, in terms of thyroidectomy and radioactive iodine 
(RAI) therapy. 
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Introduction
Thyroid nodules (TN) are extremely common in general popu-
lation and also thanks to their subclinical detection via ultrasound 
imaging (US), the incidence of thyroid cancer is increasing [1]; in 
Europe for example, it has increased in the last decade by 69% 
in men and 65% in women. In fact, it has been estimated that one 
person out of five, despite gender, age and other epidemiological 
characteristics has a palpable thyroid nodule, which can be de-
tected by US in most of cases [2]. The prevalence of TN is greater 
in women than in men, with multiple nodules that are more common 
than solitary ones [3]. In the diagnostic algorithm of TN, the differen-
tial diagnosis includes numerous clinical entities, both benign and 
malignant; therefore, the pathological examination has an important 
role in their evaluation. Thanks to fine needle aspiration cytology 
(FNAC) biopsy the identification of high-risk situations has signifi-
cantly improved so that their management has now become more 
effective [4]. However, there are still cases in which patients require 
surgery for further confirmation of the disease, thus relying upon 
the pathologist to correctly characterize their nodule [4].
Thyroid cancer (TC) instead, despite being the most common 
endocrine tumor, represents less than 1% of all newly diagnosed 
malignancies [2]. From a histological point of view, follicular 
cells within the thyroid gland are responsible for tumorigenesis and 
generate three main types of differentiated thyroid cancer (DTC): 
papillary (PTC), follicular (FTC) and mixed cell variants, which 
account for approximately 95% of all thyroid carcinoma, all of 
which are commonly well differentiated therefore these tumors are 
iodine avid and diagnosed/treated with I-123 or I-131, although 
they also include many subtypes that have different outcomes in 
terms of response to therapy and prognosis [5]. Undifferentiated 
and anaplastic tumors are not always iodine avid due to tumor 
dedifferentiation, which can occur even in case of tumor recurrence 
[5]. When thyroid neoplastic lesions lose the ability to synthesize 
hormones from iodine, they show increased glucose metabolism; 
therefore, patients will have high human thyroglobulin levels and 
negative I-131 scans. In such selected cases, with a high clinical 
suspicion for disease but negative I-131 scan, positron emission 
tomography/computed tomography (PET) with F-18-Fluorodeox-
yglucose (FDG) could be helpful in the detection of disease and 
the definition of its extent [6]. The most recent American Thyroid 
Association (ATA 2015) guidelines for the management of adult 
patients with Thyroid Nodules and Differentiated Thyroid Cancer 
recommend total thyroidectomy for tumors greater than 1 cm and 
possible lobectomy for tumors ≤ 1 cm. In general, PTC and FTC 
prognoses are very good, with low risk of recurrence and distant 
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metastases; however, there are marked differences between the 
two groups [7]. In fact, PTC patients are usually younger than 50 
years old, with smaller tumors and higher incidence of lymph node 
metastases, whereas FTC patients show more frequently distant 
metastatic disease and receive radioiodine [8]. In addition to these 
prognostic factors, more recently, the role of oncogenic mutations in 
the tumorigenesis of TCs has become clearer [9]. Among such mu-
tations, BRAFV600E represents the most common genetic alteration 
in PTC, with approximately 45% prevalence. In fact, compared to 
PTC patients without BRAF mutation, positive ones tend to present 
at higher stage and with more frequent distant metastases [10]. 
Thus, mutated BRAF may define a more aggressive papillary car-
cinoma with poorer prognosis and therefore its analysis has been 
extensively studied as a rule-in test for thyroid carcinoma [11].
In this paper, we try to outline the possible role of FDG PET/CT 
in the management of patients with DTC and positive BRAF muta-
tions and the impact that it could have on their therapeutic algorithm, 
in terms of thyroidectomy and radioactive iodine (RAI) therapy. 
Molecular pathophysiology
Thyroid epithelial cells have a transport mechanism, the so-
dium/iodide symporter (NIS), which enables thyroid concentration 
of iodide to subsequently undergoe organification and incorporation 
into thyroid hormones [12]. This mechanism is influenced primar-
ily by a pituitary hormone, the thyroid-stimulating hormone (TSH), 
which increases the transport of iodide [13]. B-type RAF kinase 
(BRAF) is a serine-threonine kinase that belongs to the rapidly 
accelerated fibrosarcoma (RAF) family, and represents the most 
potent mitogen activated protein kinase (MAPK) pathway activator 
[14]. The MAPK pathway is a signal transduction cascade driven 
by phosphorylation that leads to intracellular responses such 
as cell proliferation [15]. Thus, BRAF acts as a protooncogene and 
has an important function in cell growth, differentiation and apopto-
sis, with its point mutations that have been noted in various human 
cancers [16]. In PTC, a common mutation in the BRAF gene com-
prises a missense mutation that consists of a thymine-to-adenine 
transversion at nucleotide 1799 (T1799A) within exon 15, which 
leads to the substitution of a valine residue for a glutamate one 
at position 600 of the protein (V600E), with consequent gain of 
function, constitutive activation of MAPK pathway, i.e. BRAFV600E 
activating mutation is associated with tumorigenesis [17].
FDG PET/CT is routinely used to evaluate disease burden in 
a variety of neoplasms, with FDG uptake that is based on enhanced 
aerobic glycolysis in cancer cells, known as Warburg effect. In TC 
there is an inverse relationship between FDG avidity and radioiodine 
uptake mainly in case of metastatic lesions, a phenomenon which 
was originally described as ‘flip-flop’ [18–20]. 
Thyroid nuclear medicine imaging
Thyroid gland imaging is routinely done with different radiop-
harmaceuticals that are used in specific clinical contexts. Among 
them, Tc-99m-pertechnetate is widely used and owes its popular-
ity to easy availability, low absorbed radiation dose compared to 
I-123 or I-131 and lower costs. The tracer is trapped by the thyroid, 
but it does not undergo organification, remaining in the gland 
for a relatively short period which allows imaging for diagnostic 
purposes mainly related to thyroid morphology and function, i.e 
hypo- or hyper-thyroidism [21].
99mTc-MIBI scintigraphy instead is more suitable than 
99mTc-pertechnetate scintigraphy for TN differentiation between 
benign and malignant lesions, since nodules with increased uptake 
and late retention of 99mTc-MIBI are more suspicious for malignancy 
(sensitivity 82%, specificity 63%) [22].
Iodide radioisotopes (I-123, I-131) are trapped and organi-
fied inside the thyroid providing higher thyroid-to-background 
uptake ratios; however, in order to achieve sufficient iodine uptake 
into tumor cells, high levels of TSH are required (serum TSH lev-
els > 30 mUI/L), thus implying either thyroid hormone withdrawal 
or intramuscular injection of rh-TSH (Thyrogen©). I-123 and I-131 
could be used to interrogate the NIS symporter to assess thyroid 
nodule functioning in order to distinguish “hot” (autonomous) from 
“cold” (hypofunctioning) nodules but their main application is the 
detection of thyroid cancer metastases, which as the primary tumor 
are usually iodine avid [23].
FDG PET/CT in the management of patients 
with DTCs
As stated above, due to either BRAFV600E mutation or tumor 
dedifferentiation, when the ability to synthesize hormones from 
iodine is lost, tumors show increased glucose metabolism [24]. In 
such cases, patients will present with elevated human thyroglobu-
lin levels (i.e. serum specific marker of TC) and with negative 
post-therapeutic I-131 whole body scans. Here, FDG PET/CT, better 
if performed after TSH stimulation analogously to patient prepara-
tion done for radioiodine scintigraphy, could be useful mainly in the 
detection of metastatic and recurrent disease since the uptake and 
diagnostic sensitivity of FDG are increased by TSH stimulation [25]. 
In fact, although the current ATA guidelines do not routinely recom-
mended FDG-PET/CT for the diagnostic workup of indeterminate 
thyroid nodules due to limited clinical validation, several studies and 
meta-analysis already demonstrated the opposite [7].
More in particular in a recent paper by Piccardo et al., the 
Authors compared the accuracy of FDG PET/CT with Tc-99m-MIBI 
scintigraphy and multiparametric neck ultrasonography (US) dem-
onstrating that the former has significantly higher performances in 
terms of sensitivity and NPV than the latters [26]. They also evalu-
ated the possible role of FDG PET/CT in different diagnostic con-
texts in terms of impact on clinical management. It emerged that 
FDG PET/CT could be of use already at a preoperative stage to 
define the nature of indeterminate TNs thanks to its high sensitivity 
and NPV, especially in patients with lesions > 15mm with sensitiv-
ity ranging from 77 to 100% and NPV from 81 to 100% [26]. More 
specifically, we know that focal uptake of FDG within the thyroid 
gland, as incidental finding during evaluation of non-thyroid can-
cers, may be related to both benign and malignant pathology 
[27]. In this sense, De Koster et al. suggested that the number of 
futile hemithyroidectomies for benign nodules could be reduced 
thanks to the implementation of FDG-PET/CT by 66%, implying the 
cost-effectiveness of this technique in the pre-operative setting [28]. 
However, overall reported sensitivity and specificity of FDG-PET/CT 
in this specific scenario ranged from 77% to 100% and from 33% 
to 64%, respectively, with small nodule size being the main reason 
for false-negativity, since FDG-avidity in very small nodules may 
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be missed due to both low volume of malignant cells and partial 
volume effect, which underestimate the real FDG-concentration 
[28]. Moreover, the radiation exposure of FDG-PET/CT that pa-
tients should undergo before surgery represents another limitation 
to this possible application since it is largely accounted for by the 
FDG dosage (approximately 3 to 4 mSv for a typical activity of 185 
MBq administered to an average adult) whereas the CT radiation 
dose greatly varies, being less than 0.5 mSv for a low-dose CT of 
the neck region only [29].
Pre-operative FDG PET/CT could also be used in the assess-
ment of biological behavior of DTCs in order to predict the ag-
gressiveness of the tumor pre-surgically [30]. In this sense, BRAF 
molecular test already represents the most reliable tool to identify 
the most aggressive subgroup of papillary thyroid carcinomas, 
but due to the relatively high costs and low availability, its use 
in clinical practice remains not applicable [31, 32]. Therefore, 
as some studies report, FDG PET/CT could be used to reduce 
costs and provide analogous information, with a more intense 
FDG uptake at pre-operative PET/CT that might be associated 
with a poorer prognosis and more aggressive histological subtype 
[33]. In this sense, Trimboli and colleagues used a SUV ratio of 3.0 
as a cut-off to distinguish patients with higher rather than lower risk 
of disease progression. However, after a multivariate analysis, they 
concluded that only tumor size remained associated with disease 
persistence/progression; therefore, the evidence of this possible 
application of FDG PET/CT remains to be further evaluated [34].
Recent 2015 ATA Guidelines recommend neck US as first-line 
imaging technique to stage DTCs before thyroidectomy, where-
as the use of CT or multiparametric magnetic resonance imaging 
(MRI) is reserved for high risk patients in which the probability to 
have distant metastases or mediastinal/neck nodal involvement at 
time of diagnosis is elevated [7]. In this context PET/CT does not 
have a role yet, even if some studies have been already published 
in this sense [35]. Specifically, Agate et al. compared the perfor-
mance of FDG PET/CT, CT alone and US in the diagnosis of cervical 
lymph node metastasis in patients with PTC and concluded that US 
had the best diagnostic accuracy among the three (64.9%, 61.9% 
and 82% respectively) thus confirming ATA guidelines preference 
of neck US as best methodology for preoperative assessment of 
nodal status. However, FDG PET/CT might still be useful in aggres-
sive DTC subtypes such as tall-cell, solid/trabecular, insular and 
diffuse sclerosing or in patients with suspected distant metasta-
ses for staging purposes and to predict the preoperatively the risk 
of recurrence [37]. A Japanese group retrospectively analyzed in 
a recent paper the benefit of FDG PET/CT at initial diagnosis in 
114 patients with DTC for predicting the high-risk for recurrence by 
assessing seven parameters including among the others SUVmax, 
SUVmean and MTV (metabolic tumor volume expressed in cm3). 
They identified 88 patients with FDG-avid tumor and 26 patients with 
FDG-non-avid tumor and demonstrated that the former group 
resulted to have significantly larger lesions (21 vs 13 mm), more 
advanced ATA-risk classification, but at the same time, only 10 out 
of 88 patients were classified as high-risk and the parameters them-
selves revealed a wide range of sensitivity, specificity and accuracy. 
So, they divided patients according MTV, if greater than 10.0 cm3 
or not, and introduced a scoring system that takes in considera-
tion each of the seven diagnostic parameters assigning a score 
of 0 if negative for high-risk or 1 if positive using each threshold 
criterion. Summing these scores to differentiate between high-risk 
and non-high-risk patients they demonstrated that a summed 
score ≥ 5 in 44 patients with an MTV > 10.0 cm3 was associated 
with 100% sensitivity, 91.7% specificity and 93.2% accuracy (AUC: 
0.98) in predicting the high-risk for recurrence. Therefore, they 
concluded that FDG-non-avid primary DTCs are less inclined to 
post-operative recurrence whereas in FDG-avid primary DTCs with 
MTV > 10.0 cm3, the combination of SUV-related, volumetric and 
texture parameters could significantly increase the ability to identify 
high-risk patients, thus confirming the prognostic value of FDG PET 
in advanced thyroid cancer [38].
Apart from the aforementioned scenarios in which FDG PET/CT 
might have or not a role in clinical practice, what remains clear 
as main indication for this technique is the post-operative stage, 
during follow-up, mainly in case of patients with aggressive histolo-
gies so to have a starting reference point or in chase of high or 
increasing Tg levels (Tg > 10 ng/mL or doubling time of less than 
1 year) with negative post-therapeutic I-131 whole-body scan [39]. 
A meta-analysis performed by Wan et al. [40] evaluated 17 stud-
ies with 571 patients who had recurrent or metastatic DTC and 
I-131 negative whole-body scan and determined that FDG-PET/CT 
a pooled sensitivity and specificity of 93.5% and 83.9%, respectively, 
with an overall diagnostic accuracy of 90.9%. Moreover, studies have 
shown that the positivity rate of FDG-PET/CT increases as Tg level 
rises, though there is lack of consensus on what the precise thresh-
old level of Tg should be since positive findings have also been 
reported in 10–20% of DTC patients with Tg levels < 10 ng/mL [41]. 
In this sense, becomes crucial the comparison of post-therapeutic 
I-131 whole-body scan with FDG-PET/CT because the latter could 
be helpful in the reduction of unnecessary second administration 
of high I-131 activities, which means direct implication on patients’ 
clinical management [42]. In fact, the current guideline to define 
a radioactive iodine-refractory (RAIR) DTC is based on the clinical 
negative response to a cumulative I-131 dose of 600 mCi or more, 
which means at least 3 RAI therapies over a two-year period, tak-
ing in consideration a 6-month treatment interval [43]. This may 
lead to a therapeutic delay, i.e. to not receive an appropriate 
treatment at the earliest possibility [44]. FDG-PET/CT could be 
useful in this sense as an early response predictor, thus allowing 
the early implementation of alternate therapies such as Tyrosine 
Kinase Inhibitors (TKIs). Kang et al. recently studied this problem 
by evaluating 54 patients with metastatic DTC who underwent both 
RAI therapy scan and FDG PET/CT during the same period in order 
to predict the response rate of RAI itself. Of 54 patients, only 22 had 
a therapeutic response to RAI with a 43% rate of concordance 
between the two techniques and with significant negative correla-
tion between FDG avidity of metastatic lesions and response rate. 
Therefore, they concluded that the patient group with FDG-avid 
metastasis showed poor response to RAI therapy regardless of the 
degree of RAI uptake at I-131 whole-body scan [45].
BRAFV600E and FDG PET/CT
Recent clinical studies demonstrated the relationship between 
BRAFV600E mutation and FDG uptake, showing that BRAFV600E muta-
tion is associated with downregulation of the NIS symporter, loss of 
RAI avidity and increased glucose transporter (GLUT-1) expression 
in both primary and metastatic PTCs, thus determining poorer 
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prognosis, including events such as increased incidence of recur-
rence, extrathyroidal invasion and distant metastases [46]. More in 
particular, in BRAFV600E-positive PTCs, several studies demonstrated 
that at mitochondrial level there is a reduction of O2 consumption 
and increased glucose uptake, thus favoring an anaerobic glycolytic 
shift in cancer cells by targeting at transcriptional level both hypoxia 
inducible factor (HIF)-1 that acts on GLUT1, GLUT3 and hexokinase 
II, which play an important role in trapping FDG inside cancer 
cells and the M2 isoform of pyruvate kinase (the rate-limiting step 
of glycolysis) which showed significantly higher levels compared 
to BRAF wild-type PTCs [47]. Therefore, the association between 
BRAFV600E mutation and FDG uptake could be explained with the 
induction of MAPK transduction pathway and the subsequent ac-
tivation of HIF-1 resulting in increased glycolysis and loss of RAI 
avidity [48]. In this sense, as a recent study reported, BRAFV600E 
mutations were present in 62% of RAIR recurrent/metastatic TCs; 
analogously, all patients with RAIR PTCs and FDG-PET/CT positive 
scan were BRAFV600E-positive, compared to 45% of positive PET/CT 
scans in PTCs in general [49]. In a recent meta-analysis, Santhanam 
and colleagues not only show the significant correlation in DTC 
patients between BRAFV600E-positiveness and the higher odds of 
having FDG-PET/CT avid lesions (OR = 2.12) but they also dem-
onstrated that these patients tend to have relatively higher mean 
SUV values (although SUV values may vary greatly across institu-
tions and the measurement itself depends on multiple factors), 
thus concluding that BRAFV600E mutation, when present, should 
prompt the treating clinician to consider FDG-PET/CT as a useful 
diagnostic test to localize residual disease [46]. Nagarajah et al. 
[50] specifically evaluated the differences in terms of glucose me-
tabolism of the BRAFV600E versus BRAFWT in patients with DTC and 
poorly differentiated TCs. While in the first cohort median SUVmax 
was significantly higher in the mutated group versus wild-type 
(median SUVmax 6.3 versus 4.7), in the latter FDG uptake was not 
significantly different between the two groups.
A very interesting study design instead, was carried out by Choi 
et al. that retrospectively reviewed 106 patients with PTC who un-
derwent FDG PET/CT scan before undergoing total thyroidectomy, 
scans that were subsequently compared with clinicopathological 
data collected from surgical specimens, such as primary tumor 
size, capsular invasion, metastases and BRAFV600E mutation among 
the others. 
Reported SUVmax was significantly higher in primary tumors of 
size greater than 1 cm (SUVmax 6.6 vs 3.4), in PTCs with extra-thy-
roid extension of the tumor (SUVmax 5.8 vs 3.7) and in PTCs with 
BRAFV600E mutation (SUVmax 5.7 vs 3.0), whereas at a multivariate 
analysis only tumor size and BRAFV600E were significantly associ-
ated with the SUVmax of the primary tumor, as extra-thyroid exten-
sion and thyroid capsular invasion had no statistically significant 
association. Therefore, they concluded that FDG PET/CT may 
play an important role and yield additional information on tumor 
aggressiveness when associated to molecular biomarkers such 
as BRAFV600E mutation [51].
Conclusions
Differentiated thyroid cancers are the most common histologi-
cal types of thyroid cancer which are characterized by a favorable 
prognosis thanks to surgical removal of the tumor and radioiodine 
ablation therapy, with an overall 5-year survival rate higher than 
90%. However, in some patients we can have a more aggressive 
behavior that often becomes the cause of mortality due to tumor 
recurrence and RAI refractoriness. Neck US still represents the 
first-line imaging technique to stage DTCs before thyroidectomy 
and is the best methodology for preoperative assessment of nodal 
status; however, new possible scenarios of application seem to 
be possible when this PET/CT is associated with the presence of 
molecular biomarkers, such as BRAFV600E mutation. FDG PET/CT 
has already been used in clinical practice in cases of elevated serum 
thyroglobulin and negative I-131 whole-body scintigraphy, mainly to 
locate recurrent disease and for its prognostic role. Unfortunately, 
despite these promising reports, the relationship between F-18 
FDG uptake and the BRAFV600E mutation for a possible pre-operative 
application is still poorly recognized as it will need further validation 
in consideration also of the genetic heterogeneity that has been 
reported (between different primary tumors and regional lymph 
node metastases), which requires that all lesions within the patient 
harbor the same genetic defect. 
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